[{"data":1,"prerenderedAt":235},["ShallowReactive",2],{"story-112144-tw":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":33,"questions":34,"relatedArticles":59,"body_color":233,"card_color":234},"112144",null,"Grail's Failed Cancer Test Signals Health-Tech Credibility Crisis | Sellers Must Tighten Evidence Claims","- 47-50% stock collapse on Feb 19, 2026 reveals investor demand for clinical proof; health/wellness sellers face stricter platform policies on diagnostic marketing claims",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32],"https://schaeffers-cdn.s3.amazonaws.com/images/default-source/schaeffers-cdn-images/default-images/charts/bigstock-concept-of-economic-crisis-wit-417535732.jpg?sfvrsn=7a1bd806_4","https://menafn.com/updates/pr/2026-02/20/AN_web-p_2f7c4image_story.webp","https://pubimg.futunn.com/20220509000002914f8cb245ecb.jpg","https://sherwoodnews.imgix.net/galleri_grail.png?w=1600","https://cdn.benzinga.com/files/images/story/2026/02/20/cancer.jpeg?width=1200&height=800&fit=crop","https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg","https://images.barrons.com/im-20081944?width=700&height=466","https://images.wsj.net/im-925349/social","https://s.yimg.com/ny/api/res/1.2/5cu2SM5w0bEzKooAZPaV_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/marketbeat_955/095cbc1edfef2a7cde1e35b7078d4a61","https://i0.wp.com/tvdelmarva.com/wp/wp-content/uploads/2026/02/news-1771597142358.png?resize=1920%2C1080&ssl=1","https://tokenist.com/wp-content/uploads/2026/02/123973438_m-646x360.jpg","https://static01.nyt.com/images/2026/02/21/multimedia/21HS-CANCER-TEST/21HS-CANCER-TEST-articleLarge.jpg?quality=75&auto=webp&disable=upscale","https://news.stocktwits-cdn.com/large_Getty_Images_2164981884_1_jpg_100f5d0da3.webp","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1183370025.jpg?VersionId=GKqNguxcpF7FBV2w2z7fpvYFLn.s747F","https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/large_stock_down_resized_901c19c371.jpg","https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_preview_8.jpg?width=1200&height=800&fit=crop","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://www.statnews.com/wp-content/uploads/2025/10/AdobeStock_684400241_Editorial_Use_Only-645x645.jpeg","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-05-19T055248Z_1_LYNXMPEL4I06W_RTROPTP_3_BRITAIN-EU-MARKETS.JPG","https://www.reuters.com/resizer/v2/YQJM36ZWSJMF7BLNW52IXEZYV4.jpg?auth=37d8d6f82111198e1cf853c6732fa5df28fcc1f2946352ec5575dcc654c447b8&height=628&width=1200&quality=80&smart=true","https://pharmaphorum.com/sites/default/files/styles/x_large/public/2026-02/Grail_NHS-Galleri_trial_image_1200x675.jpg?itok=qB1mZvXL","https://mma.prnewswire.com/media/2460831/Grail_Logo.jpg?p=facebook","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/528559388/image_528559388.jpg?io=getty-c-w1280","**Clinical trial failure reshapes health-tech investment landscape and e-commerce platform policies.** Grail's Galleri blood test, positioned as a breakthrough multi-cancer detection technology, failed to meet its primary endpoint in a landmark NHS study involving 142,000 participants announced February 19-20, 2026. The test did not demonstrate statistically significant reduction in Stage III-IV cancer diagnoses, despite generating $136.8 million in U.S. revenue from 185,000 tests sold in 2025 at $1,000 per test. Grail's stock plummeted 45-50% in after-hours trading, with some reports citing 30% declines, reflecting investor focus on clinical outcomes over financial performance—the company reported better-than-expected Q4 losses ($2.44 vs. $4.01 per share consensus) and 14-17% revenue growth, yet markets punished the regulatory setback.\n\n**This outcome carries critical implications for e-commerce sellers in health and wellness categories.** The trial failure demonstrates how clinical evidence directly influences investor confidence, regulatory pathways, and platform policies. Amazon, eBay, and Shopify increasingly scrutinize health product marketing claims following high-profile failures like this. Sellers marketing diagnostic tests, wellness supplements, or health-tech devices must now provide robust clinical evidence or face delisting, account suspension, or policy violations. The gap between Grail's aggressive Super Bowl marketing (partnership with Hims & Hers) and trial results illustrates the credibility crisis: promising preliminary data no longer satisfies investors or regulators. Grail plans to extend trial follow-up 6-12 months and present detailed analysis at the American Society of Clinical Oncology conference in spring 2026, signaling that FDA approval remains uncertain despite commercial operations under regulatory exemptions.\n\n**Broader liquid biopsy sector faces investor skepticism and regulatory tightening.** The trial failure raises fundamental questions about whether detecting cancer DNA presence alone translates to improved patient outcomes—a distinction critical for Medicare coverage decisions and insurance reimbursement. Congress recently authorized Medicare coverage for cancer detection tests via Trump-signed spending package, but this setback will likely trigger stricter evidence standards before reimbursement approval. For sellers, this means: (1) health-tech partnerships with struggling companies face supply chain risk; (2) platform policies on diagnostic marketing will tighten; (3) consumer trust in unproven screening tests erodes, reducing demand for related products; (4) regulatory scrutiny of health claims intensifies across all e-commerce channels. The disconnect between Grail's financial performance (17% YoY sales growth to $147.2 million) and stock collapse (47% decline) reveals that clinical validation now outweighs revenue metrics in biotech valuation—a shift that will cascade into platform enforcement of evidence-based health marketing standards.",[35,38,41,44,47,50,53,56],{"title":36,"answer":37,"author":5,"avatar":5,"time":5},"What supply chain risks emerge from Grail's regulatory setback?","Grail's failure to achieve FDA approval (operating under regulatory exemptions since 2021) creates supply chain uncertainty for sellers partnering with health-tech companies. The company plans 6-12 month trial extension and spring 2026 ASCO conference presentation, delaying approval decisions. Sellers should: (1) diversify supplier relationships away from pre-approval biotech companies; (2) avoid exclusive partnerships with companies lacking FDA clearance; (3) monitor regulatory announcements monthly through FDA.gov; (4) build 90-day inventory buffers for products dependent on uncertain approvals. Companies with pending FDA decisions face 40-60% valuation risk, affecting supply agreements and payment terms.",{"title":39,"answer":40,"author":5,"avatar":5,"time":5},"How does this trial failure impact consumer demand for wellness screening products?","Grail sold 185,000 tests in 2025 at $1,000 each despite lacking FDA approval, but trial failure will reduce consumer trust in unproven screening tests. The gap between marketing claims (detect 50+ cancer types) and clinical reality (no Stage III-IV reduction) erodes confidence in similar products. Sellers in wellness categories should expect 15-25% demand decline for diagnostic/screening products through Q2 2026. Consumer skepticism will shift purchasing toward established, FDA-approved alternatives. Sellers should pivot marketing from disease-detection claims to general wellness and prevention messaging. Demand recovery depends on positive ASCO conference results (spring 2026) or FDA approval announcement.",{"title":42,"answer":43,"author":5,"avatar":5,"time":5},"What regulatory changes should sellers anticipate following this setback?","FTC and FDA will likely issue stricter guidance on health product marketing claims by Q2 2026. Grail's aggressive marketing despite unproven efficacy triggered regulatory attention; expect enforcement actions against similar companies. Sellers should anticipate: (1) stricter substantiation requirements for disease-related claims; (2) platform policies requiring pre-market clinical evidence; (3) increased FTC scrutiny of telehealth partnerships (Hims & Hers featured Galleri); (4) Medicare coverage restrictions for unproven diagnostics. Sellers should monitor FTC.gov and FDA.gov for guidance updates monthly. Non-compliance penalties range from $5,000-$50,000 per violation, plus account suspension on major platforms.",{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"How should sellers evaluate partnerships with health-tech companies after Grail's failure?","Grail's 47-50% stock collapse demonstrates that clinical trial outcomes directly impact company viability and supply reliability. Before partnering with health-tech companies, sellers should: (1) verify FDA approval status (Grail operated under exemptions, not full approval); (2) review clinical trial timelines and endpoints; (3) assess cash runway and funding (Grail reported $99.2M Q4 losses); (4) require supply agreements with 90-day termination clauses; (5) avoid exclusive partnerships with pre-approval companies. Request quarterly updates on regulatory progress and clinical trial results. Companies with pending FDA decisions face 12-24 month approval delays; build contingency plans for supply disruption. Risk assessment should weight clinical evidence as heavily as financial metrics.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"What are the cross-border implications of Grail's trial failure for international sellers?","Grail's NHS trial failure in the UK signals that European healthcare systems will tighten clinical evidence standards for cancer diagnostics, affecting sellers of medical devices and diagnostics across EU markets. The EMA (European Medicines Agency) may align with NHS procurement standards, creating uniform tightening across Europe. Cross-border sellers should monitor UK MHRA and EU EMA guidance updates over the next 2-3 quarters for new clinical evidence requirements. For sellers distributing medical supplies to European biotech firms, assess whether suppliers have adequate cash reserves to weather potential revenue declines if European healthcare systems reduce Galleri procurement. Consider shifting inventory focus toward compliance and validation solutions for European markets, where regulatory tightening is likely to accelerate. Currency volatility may also increase as biotech stocks decline, affecting cross-border pricing and payment terms—implement hedging strategies for suppliers with significant exposure to clinical trial outcomes.",{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"How does Grail's trial failure affect health product sellers on Amazon and eBay?","Grail's 47-50% stock collapse on February 19, 2026, signals that Amazon and eBay will tighten enforcement of health product marketing claims. The trial failure—where a $1,000 test with $136.8M annual revenue failed to reduce late-stage cancer diagnoses—demonstrates that platforms now prioritize clinical evidence over sales performance. Sellers marketing diagnostic tests, wellness devices, or health supplements must provide peer-reviewed clinical studies or face delisting. Amazon's health product policy explicitly requires substantiation for disease-related claims; this setback will trigger stricter audits. Sellers should audit all product listings for unsupported health claims and prepare clinical evidence documentation by March 2026.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"What does the Galleri test failure mean for Medicare coverage of diagnostic products?","Congress recently authorized Medicare coverage for cancer detection tests via Trump-signed spending package, but Grail's NHS trial failure—which showed no statistically significant reduction in Stage III-IV cancers despite 142,000 participants—will likely delay or restrict reimbursement approval. Medicare now requires stronger clinical evidence before covering new diagnostic tests. Sellers partnering with diagnostic companies or selling complementary health products should monitor CMS coverage decisions through spring 2026. The failure suggests Medicare will demand mortality benefit data, not just detection capability. This extends approval timelines 12-24 months and reduces market size for related products.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"How should sellers respond to platform crackdowns on health-tech marketing?","Immediate action required: audit all health product listings for unsubstantiated claims by March 15, 2026. Grail's Super Bowl marketing (partnership with Hims & Hers) faced credibility collapse after trial failure, signaling that aggressive health claims now trigger platform enforcement. Sellers should: (1) remove disease-prevention language unless backed by published clinical trials; (2) replace benefit claims with ingredient/feature descriptions; (3) add disclaimers that products are not FDA-approved treatments; (4) document clinical evidence in seller notes for platform review. Amazon and Shopify are implementing stricter health product policies following this incident. Non-compliance risks account suspension and 30-day delisting.",[60,65,70,74,79,83,86,90,94,98,102,105,110,114,119,123,126,130,134,139,143,147,152,156,160,163,167,171,175,179,183,188,192,196,201,205,209,213,218,222,225,229],{"id":61,"title":62,"source":63,"logo":5,"time":64},449550,"GRAIL, Inc (GRAL) Tops Q4 2025 Earnings Estimates — EPS $-2.46 vs $-3.26 Expected","https://news.alphastreet.com/gral-breaking-20260218/","2天前",{"id":66,"title":67,"source":68,"logo":27,"time":69},449693,"Key study of Grail’s cancer detection test fails in setback for company","https://www.statnews.com/2026/02/19/grail-cancer-test-galleri-results/","1天前",{"id":71,"title":72,"source":73,"logo":18,"time":69},449692,"GRAIL Q4 Earnings Call Highlights","https://finance.yahoo.com/news/grail-q4-earnings-call-highlights-021047443.html",{"id":75,"title":76,"source":77,"logo":12,"time":78},449552,"GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results","https://news.futunn.com/en/post/68956943/grail-to-announce-fourth-quarter-and-full-year-2025-financial","4天前",{"id":80,"title":81,"source":82,"logo":5,"time":69},449695,"Grail shares plunge on mixed cancer trial data and steep losses","https://www.investing.com/news/earnings/grail-shares-plunge-on-mixed-cancer-trial-data-and-steep-losses-4514885",{"id":84,"title":76,"source":85,"logo":28,"time":78},449551,"https://www.marketscreener.com/news/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results-ce7e5dd8d981f421",{"id":87,"title":88,"source":89,"logo":24,"time":69},449694,"GRAL Stock Slumps 48% After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses","https://stocktwits.com/news-articles/markets/equity/gral-stock-slumps-after-hours-as-trial-for-cancer-test-fails-to-show-reduction-in-late-stage-diagnoses/cZRkW0iR4D0",{"id":91,"title":92,"source":93,"logo":25,"time":64},449549,"A Glimpse of GRAIL's Earnings Potential","https://www.benzinga.com/insights/earnings/26/02/50696708/a-glimpse-of-grails-earnings-potential",{"id":95,"title":96,"source":97,"logo":5,"time":69},449548,"All eyes on Grail earnings as cancer test nears FDA decision","https://ng.investing.com/news/earnings/all-eyes-on-grail-earnings-as-cancer-test-nears-fda-decision-93CH-2349631",{"id":99,"title":100,"source":101,"logo":5,"time":69},450437,"GRAIL announces primary results of the NHS-Galleri randomized controlled clinical trial.","https://news.futunn.com/en/post/69047442/grail-announces-primary-results-of-the-nhs-galleri-randomized-controlled",{"id":103,"title":81,"source":104,"logo":5,"time":69},451449,"https://in.investing.com/news/earnings/grail-shares-plunge-on-mixed-cancer-trial-data-and-steep-losses-5248384",{"id":106,"title":107,"source":108,"logo":5,"time":109},452759,"Grail shares plunge after major cancer screening trial misses main goal","https://www.marketscreener.com/news/grail-shares-plunge-after-major-cancer-screening-trial-misses-main-goal-ce7e5ddddc81f622","18小時前",{"id":111,"title":112,"source":113,"logo":5,"time":69},450436,"GRAIL reiterates 22%-32% Galleri sales growth guidance for 2026 while expanding sales force after NHS-Galleri trial","https://www.msn.com/en-us/health/other/grail-reiterates-22-32-galleri-sales-growth-guidance-for-2026-while-expanding-sales-force-after-nhs-galleri-trial/ar-AA1WHKoL",{"id":115,"title":116,"source":117,"logo":32,"time":118},451448,"Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction","https://seekingalpha.com/news/4554477-grail-slides-as-trial-misses-primary-endpoint-fails-to-show-significant-stage-iii-iv-cancer-reduction","22小時前",{"id":120,"title":121,"source":122,"logo":5,"time":109},452757,"Grail (GRAL) Stock: Why the Biotech Crashed 50% Overnight","https://blockonomi.com/grail-gral-stock-why-the-biotech-crashed-50-overnight/",{"id":124,"title":107,"source":125,"logo":29,"time":109},452758,"https://www.reuters.com/legal/litigation/grail-shares-plunge-after-major-cancer-screening-trial-misses-main-goal-2026-02-20/",{"id":127,"title":128,"source":129,"logo":13,"time":109},452755,"Grail tanks after cancer detection test fails in key study","https://sherwood.news/markets/grail-tanks-after-cancer-detection-test-fails-in-key-study/",{"id":131,"title":132,"source":133,"logo":11,"time":109},452756,"Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone","https://menafn.com/1110768125/Why-Is-GRAL-Stock-Down-Today-Analysts-Lower-Targets-After-UK-Trial-Setback-But-Call-Selloff-Overdone",{"id":135,"title":136,"source":137,"logo":5,"time":138},451447,"Grail (GRAL) Stock Crashes 50% After NHS Cancer Trial Misses Primary Endpoint","https://coincentral.com/grail-gral-stock-crashes-50-after-nhs-cancer-trial-misses-primary-endpoint/","21小時前",{"id":140,"title":141,"source":142,"logo":16,"time":109},452753,"Grail Stock Plunges 49% After Earnings. Test Results Are to Blame.","https://www.barrons.com/articles/grail-stock-earnings-price-cancer-fda-4aae97a1?gaa_at=eafs&gaa_n=AWEtsqdgGQVMqtWgDoKn8u1AEk1vocLBLTbZjLe-3YYF3dyDIdRMVv1OQZTB&gaa_ts=699889c4&gaa_sig=XXzW2IYvM-CJUn7TZX-nEc-hLCx-joQWV_LzNq6Hz5r8ssTXyqx361Yj_2tS1jIwEaioAK721JUKUA-llWmp9g%3D%3D",{"id":144,"title":145,"source":146,"logo":19,"time":109},452754,"Cancer Test Company Stock Crashes After Clinical Trial Falls Short","https://www.finedayradio.com/news/tv-delmarva-channel-33/cancer-test-company-stock-crashes-after-clinical-trial-falls-short/",{"id":148,"title":149,"source":150,"logo":5,"time":151},452751,"Canaccord Genuity cuts Grail stock price target on trial results","https://www.investing.com/news/analyst-ratings/canaccord-genuity-cuts-grail-stock-price-target-on-trial-results-93CH-4516264","17小時前",{"id":153,"title":154,"source":155,"logo":5,"time":69},452752,"Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses","https://www.businesswire.com/news/home/20260219400297/en/Grail-Shareholders-Are-Encouraged-to-Reach-Out-to-Johnson-Fistel-for-More-Information-About-Potentially-Recovering-Their-Losses",{"id":157,"title":158,"source":159,"logo":15,"time":151},452750,"GRAIL's NHS-Galleri Trial Falls Short Of Primary Endpoint In Multi-Cancer Screening, Shares Slide","https://www.nasdaq.com/articles/grails-nhs-galleri-trial-falls-short-primary-endpoint-multi-cancer-screening-shares-slide",{"id":161,"title":100,"source":162,"logo":5,"time":69},449543,"https://news.futunn.com/en/post/69047442/grail-announces-primary-results-of-the-nhs-galleri-randomized-controlled?futusource=news_newspage_recommend",{"id":164,"title":165,"source":166,"logo":26,"time":69},449542,"GRAL: Strong commercial growth and positive trial results drive optimism for 2026 and beyond","https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2874595:0-gral-strong-commercial-growth-and-positive-trial-results-drive-optimism-for-2026-and-beyond/",{"id":168,"title":169,"source":170,"logo":5,"time":69},449547,"NHS trial: Galleri test detects 4x more key cancers, cuts Stage IV cases","https://www.stocktitan.net/news/GRAL/landmark-nhs-galleri-trial-demonstrates-a-substantial-reduction-in-gz7eoxttocu2.html",{"id":172,"title":173,"source":174,"logo":31,"time":69},449546,"GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results","https://www.prnewswire.com/news-releases/grail-reports-fourth-quarter-and-full-year-2025-financial-results-302693051.html",{"id":176,"title":177,"source":178,"logo":5,"time":69},449545,"GRAIL Q4 Loss Narrows, Revenue Rises; Shares Fall After Hours","https://www.marketscreener.com/news/grail-q4-loss-narrows-revenue-rises-shares-fall-after-hours-ce7e5ddcd18bff25",{"id":180,"title":181,"source":182,"logo":5,"time":69},449544,"GRAIL Reports Strong 2025 Growth and Galleri Trial Update","https://www.tipranks.com/news/company-announcements/grail-reports-strong-2025-growth-and-galleri-trial-update",{"id":184,"title":185,"source":186,"logo":10,"time":187},452748,"Biotech Stock Plummets on Cancer Screening Trial Results","https://www.schaeffersresearch.com/content/news/2026/02/20/biotech-stock-plummets-on-cancer-screening-trial-results","16小時前",{"id":189,"title":190,"source":191,"logo":5,"time":151},452749,"Grail (GRAL) Stock Crashes as Q4 Earnings Beat Overshadowed by Cancer Trial Results","https://parameter.io/grail-gral-stock-crashes-as-q4-earnings-beat-overshadowed-by-cancer-trial-results/",{"id":193,"title":194,"source":195,"logo":5,"time":69},452746,"Johnson Fistel Investigates Potential Claims Against Grail, Inc.","https://intellectia.ai/news/stock/johnson-fistel-investigates-potential-claims-against-grail-inc",{"id":197,"title":198,"source":199,"logo":17,"time":200},452801,"Grail Stock Tanks After Cancer-Screening Study","https://www.wsj.com/livecoverage/stock-market-today-us-gdp-report-02-20-26/card/grail-stock-tanks-after-cancer-screening-study-99ZK19eftta4VzupNuJG?gaa_at=eafs&gaa_n=AWEtsqc4qpTwt1pqynzG3s9wgAsJfv8cZKAfpnifrjnQdgGx0QIMwym7xH6-&gaa_ts=699889c4&gaa_sig=QCZsm9z8eBQrtQB2R-W8GV1Vj_ntlXhq3rqqMp2jUj2ktlzFL9YByTKFbybCkQz4X_qEAm_kCeLeQirDgobY6w%3D%3D","23小時前",{"id":202,"title":203,"source":204,"logo":14,"time":118},452747,"Why Grail Stock Is Sinking Friday","https://www.benzinga.com/news/health-care/26/02/50743507/why-grail-stock-is-sinking-friday",{"id":206,"title":207,"source":208,"logo":21,"time":109},452802,"Grail’s Cancer Detection Test Fails in Major Study","https://www.nytimes.com/2026/02/20/health/cancer-detection-test-grail.html",{"id":210,"title":132,"source":211,"logo":22,"time":212},452745,"https://stocktwits.com/news-articles/markets/equity/why-is-gral-stock-down-today-analysts-lower-targets-after-uk-trial-setback-selloff-overdone/cZRN5uHR4x9","19小時前",{"id":214,"title":215,"source":216,"logo":23,"time":217},452800,"Grail stock craters as Galleri trial fails to hit endpoint","https://www.fiercebiotech.com/medtech/grail-stock-craters-key-nhs-galleri-trial-fails-hit-significance","20小時前",{"id":219,"title":220,"source":221,"logo":5,"time":69},452762,"Why GRAIL Inc. Stock Is Sliding Despite Big Hopes","https://www.tipranks.com/news/catalyst/why-grail-inc-stock-is-sliding-despite-big-hopes",{"id":223,"title":81,"source":224,"logo":5,"time":69},452763,"https://www.streetinsider.com/General+News/Grail+shares+plunge+on+mixed+cancer+trial+data+and+steep+losses/26030642.html",{"id":226,"title":227,"source":228,"logo":30,"time":212},452760,"Grail's multi-cancer test fluffs its lines in UK trial","https://pharmaphorum.com/news/grails-multi-cancer-test-fluffs-its-lines-uk-trial",{"id":230,"title":231,"source":232,"logo":20,"time":212},452761,"GRAIL Stock Tumbles Despite EPS Beat After Cancer Trial Miss","https://tokenist.com/grail-stock-tumbles-despite-eps-beat-after-cancer-trial-miss/","#582337ff","#5823374d",1771680678699]